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ABSTRACT 
Shigella-infected bacillary dysentery or commonly known as Shigellosis is a leading cause of 
morbidity and mortality worldwide. The gradual emergence of multidrug resistant Shigella spp. 
has triggered the search for alternatives to conventional antibiotics. Phage therapy could be one 
such suitable alternative, given its proven long term safety profile as well as the rapid expansion 
of phage therapy research. To be successful, phage therapy will need an adequate regulatory 
framework, effective strategies, the proper selection of appropriate phages, early solutions to 
overcome phage therapy limitations, the implementation of safety protocols, and finally 
improved public awareness. To achieve all these criteria and successfully apply phage therapy 
against multidrug resistant shigellosis, a comprehensive study is required. In fact, a variety of 
phage-based approaches and products including single phages, phage cocktails, mutated 
phages, genetically engineered phages, and combinations of phages with antibiotics have 
already been carried out to test the applications of phage therapy against multidrug resistant 
Shigella. This review provides a broad survey of phage treatments from past to present, 
focusing on the history, applications, limitations and effective solutions related to, as well as 
the prospects for, the use of phage therapy against multidrug resistant Shigella spp. and other 
multidrug resistant bacterial pathogens. 
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